Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
Rummel, Mathias J, Prof Dr, Niederle, Norbert, Prof, Maschmeyer, Georg, Prof, Banat, G Andre, MD, von Grünhagen, Ulrich, MD, Losem, Christoph, MD, Kofahl-Krause, Dorothea, MD, Heil, Gerhard, Prof, Welslau, Manfred, MD, Balser, Christina, MD, Kaiser, Ulrich, Prof, Weidmann, Eckhart, Prof, Dürk, Heinz, MD, PhD, Ballo, Harald, MD, Stauch, Martina, MD, Roller, Fritz, MD, Barth, Juergen, Pharm, Hoelzer, Dieter, Prof, Hinke, Axel, PhD, Brugger, Wolfram, Prof
Published in The Lancet (British edition) (06.04.2013)
Published in The Lancet (British edition) (06.04.2013)
Get full text
Journal Article
Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group
Borchmann, Peter, Prof, Haverkamp, Heinz, Dipl-Math, Lohri, Andreas, MD, Mey, Ulrich, MD, Kreissl, Stefanie, MD, Greil, Richard, Prof, Markova, Jana, MD, Feuring-Buske, Michaela, MD, Meissner, Julia, MD, Dührsen, Ulrich, Prof, Ostermann, Helmut, Prof, Keller, Ulrich, MD, Maschmeyer, Georg, Prof, Kuhnert, Georg, MD, Dietlein, Markus, Prof, Kobe, Carsten, MD, Eich, Hans, Prof, Baues, Christian, MD, Stein, Harald, Prof, Fuchs, Michael, MD, Diehl, Volker, Prof, Engert, Andreas, Prof
Published in The lancet oncology (01.04.2017)
Published in The lancet oncology (01.04.2017)
Get full text
Journal Article